• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IGHV 框架区负选择的迹象与慢性淋巴细胞白血病患者总体生存较差相关。

The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.

机构信息

Department of Clinical Immunology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.

Department of Oncohematology, National Cancer Institute, 33/43 Lomonosova Str., 03022, Kyiv, Ukraine.

出版信息

Leuk Res. 2021 Nov;110:106686. doi: 10.1016/j.leukres.2021.106686. Epub 2021 Aug 25.

DOI:10.1016/j.leukres.2021.106686
PMID:34492598
Abstract

The mutational status of the variable region of the immunoglobulin heavy chain (IGHV) genes remains the most significant prognostic factor in chronic lymphocytic leukemia (CLL) patients. However, the groups of mutated (M) and unmutated (UM) patients are also heterogeneous, and additional markers are used for a more accurate prognosis. The aim of our work was to determine the prognostic value of the signs of antigen selection determined by BASELINe statistics in M IGHV sequences of CLL patients. Clinical data, IGHV gene configuration, TP53, NOTCH1, SF3B1 mutations were analyzed in 127 CLL patients with M IGHV sequences. The median OS of patients with negative selection in the framework regions (FWRs) of IGHV genes was 120 months compared to 202 month in other CLL patients (P = 0.016). In multivariate Cox regression analysis Binet stage C vs A + B (P < 0.0001), SF3B1 mutations (P < 0.0001), negative selection in the FWRs (HR P = 0.007), and age ≥65 years (P = 0.034) were powerful adverse prognostic factors for OS in CLL patients with M IGHV genes. These preliminary data suggest that the signs of antigen-driven selection may be used as a prognostic factor in CLL patients with M IGHV genes in combination with other markers.

摘要

免疫球蛋白重链(IGHV)基因可变区的突变状态仍然是慢性淋巴细胞白血病(CLL)患者最重要的预后因素。然而,突变(M)和未突变(UM)患者群体也存在异质性,需要使用其他标志物进行更准确的预后。我们的工作旨在确定 BASELINe 统计确定的抗原选择迹象在 M IGHV 序列 CLL 患者中的预后价值。分析了 127 例 M IGHV 序列 CLL 患者的临床数据、IGHV 基因构型、TP53、NOTCH1、SF3B1 突变。IGHV 基因框架区(FWRs)存在负选择的患者中位 OS 为 120 个月,而其他 CLL 患者为 202 个月(P=0.016)。在多变量 Cox 回归分析中,Binet 分期 C 与 A+B(P<0.0001)、SF3B1 突变(P<0.0001)、FWRs 负选择(HR P=0.007)和年龄≥65 岁(P=0.034)是 M IGHV 基因 CLL 患者 OS 的不良预后因素。这些初步数据表明,抗原驱动选择的迹象可以与其他标志物结合,作为 M IGHV 基因 CLL 患者的预后因素。

相似文献

1
The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.IGHV 框架区负选择的迹象与慢性淋巴细胞白血病患者总体生存较差相关。
Leuk Res. 2021 Nov;110:106686. doi: 10.1016/j.leukres.2021.106686. Epub 2021 Aug 25.
2
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.IGHV 基因同源性 98%是将中国慢性淋巴细胞白血病患者预后进行二分的最佳截断值。
Cancer Med. 2020 Feb;9(3):999-1007. doi: 10.1002/cam4.2788. Epub 2019 Dec 17.
3
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.中国慢性淋巴细胞白血病患者中SF3B1、NOTCH1、MYD88、BIRC3和IGHV突变频率及TP53基因破坏情况:与欧洲人的差异
Oncotarget. 2015 Mar 10;6(7):5426-34. doi: 10.18632/oncotarget.3101.
4
Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.塞尔维亚慢性淋巴细胞白血病患者中 IGHV-IGHD-IGHJ 重排的突变状态和基因库。
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):252-60. doi: 10.1016/j.clml.2012.03.005. Epub 2012 May 4.
5
COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.COBLL1、LPL和ZAP70的表达能够高度准确地定义慢性淋巴细胞白血病患者的预后亚组,并且与IGHV突变状态相关。
Leuk Lymphoma. 2017 Jan;58(1):70-79. doi: 10.1080/10428194.2016.1180690. Epub 2016 May 17.
6
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.一线化疗免疫治疗的慢性淋巴细胞白血病患者中基因突变和染色体异常对无进展生存期的影响:临床实践经验。
Leuk Res. 2019 Jun;81:75-81. doi: 10.1016/j.leukres.2019.04.015. Epub 2019 Apr 25.
7
Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中免疫球蛋白重链可变区突变状态与孤立性有利基线基因组畸变之间的关联
Leuk Lymphoma. 2018 Jan;59(1):59-68. doi: 10.1080/10428194.2017.1323271. Epub 2017 Jun 22.
8
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.IGHV 突变状态和负荷对慢性淋巴细胞白血病预后和预测的影响:重点关注 FCR 和 BR 治疗。
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):678-685.e4. doi: 10.1016/j.clml.2019.03.002. Epub 2019 Mar 11.
9
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).早期慢性淋巴细胞白血病(CLL)患者诊断时未发生突变的免疫球蛋白重链可变区(IGHV)独立预测首次治疗的随访时间(TTFT)较短。
Leuk Res. 2024 Aug;143:107541. doi: 10.1016/j.leukres.2024.107541. Epub 2024 Jun 13.
10
Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.除TP53和IGHV突变状态外,复杂核型在一线慢性淋巴细胞白血病中的主要预后价值。
Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.

引用本文的文献

1
Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis.慢性淋巴细胞白血病患者的预后意义:一项荟萃分析。
Ann Hematol. 2025 Aug;104(8):3943-3962. doi: 10.1007/s00277-025-06499-4. Epub 2025 Jul 30.